H
Heidrun Gevensleben
Researcher at University Hospital Bonn
Publications - 68
Citations - 3776
Heidrun Gevensleben is an academic researcher from University Hospital Bonn. The author has contributed to research in topics: Cancer & DNA methylation. The author has an hindex of 27, co-authored 67 publications receiving 2893 citations. Previous affiliations of Heidrun Gevensleben include Heinrich Pette Institute & Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat,Daniel Barrowdale,Irene L. Andrulis,Susan M. Domchek,Diana Eccles,Heli Nevanlinna,Susan J. Ramus,Amanda B. Spurdle,Mark E. Robson,Mark E. Sherman,Anna Marie Mulligan,Fergus J. Couch,Christoph Engel,Lesley McGuffog,Sue Healey,Olga M. Sinilnikova,Melissa C. Southey,Mary Beth Terry,David E. Goldgar,Frances P. O'Malley,Esther M. John,Ramunas Janavicius,Laima Tihomirova,Thomas Hansen,Finn Cilius Nielsen,Ana Osorio,Alexandra V. Stavropoulou,Javier Benitez,Siranoush Manoukian,Bernard Peissel,Monica Barile,Sara Volorio,Barbara Pasini,Riccardo Dolcetti,Anna Laura Putignano,Laura Ottini,Paolo Radice,Ute Hamann,Muhammad Usman Rashid,Frans B. L. Hogervorst,Mieke Kriege,Rob B. van der Luijt,Susan Peock,Debra Frost,D. Gareth Evans,Carole Brewer,Lisa Walker,Mark T. Rogers,Lucy Side,C. E. Houghton,Jo Ellen Weaver,Andrew K. Godwin,Rita K. Schmutzler,Barbara Wappenschmidt,Alfons Meindl,Karin Kast,Norbert Arnold,Dieter Niederacher,Christian Sutter,Helmut Deissler,Doroteha Gadzicki,Sabine Preisler-Adams,Raymonda Varon-Mateeva,Ines Schönbuchner,Heidrun Gevensleben,Dominique Stoppa-Lyonnet,Muriel Belotti,Laure Barjhoux,Claudine Isaacs,Beth N. Peshkin,Trinidad Caldés,Miguel De Al Hoya,Carmen Cañadas,Tuomas Heikkinen,Päivi Heikkilä,Kristiina Aittomäki,Ignacio Blanco,Conxi Lázaro,Joan Brunet,Bjarni A. Agnarsson,Adalgeir Arason,Rosa B. Barkardottir,Martine Dumont,Jacques Simard,Marco Montagna,Simona Agata,Emma D'Andrea,Max Yan,Stephen B. Fox,Timothy R. Rebbeck,Wendy S. Rubinstein,Nadine Tung,Judy Garber,Xianshu Wang,Zachary S. Fredericksen,Vernon S. Pankratz,Noralane M. Lindor,Csilla Szabo,Kenneth Offit,Rita A. Sakr,Mia M. Gaudet,Christian F. Singer,Muy Kheng Tea,Christine Rappaport,Phuong L. Mai,Mark H. Greene,Anna P. Sokolenko,Evgeny N. Imyanitov,Amanda E. Toland,Leigha Senter,Kevin Sweet,Mads Thomassen,Anne-Marie Gerdes,Torben A Kruse,Maria A. Caligo,Paolo Aretini,Johanna Rantala,Anna Von Wachenfeld,Karin M. Henriksson,Linda Steele,Susan L. Neuhausen,Robert L. Nussbaum,Mary S. Beattie,Kunle Odunsi,Lara Sucheston,Simon A. Gayther,Katherine L. Nathanson,Jenny Gross,Christine Walsh,Beth Y. Karlan,Georgia Chenevix-Trench,Douglas F. Easton,Antonis C. Antoniou +132 more
TL;DR: Pathologic characteristics of BRCA1 and BRCa2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis.
Journal ArticleDOI
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen Sandhu,Shahneen Sandhu,William R. Schelman,George Wilding,Victor Moreno,Richard D. Baird,Susana Miranda,Lucy Hylands,Ruth Riisnaes,Martin Forster,Aurelius Omlin,Nathan Kreischer,Khin Thway,Heidrun Gevensleben,L. Sun,John W. Loughney,Manash Shankar Chatterjee,Carlo Toniatti,Carlo Toniatti,Christopher L. Carpenter,Robert Iannone,Stan B. Kaye,Johann S. de Bono,Robert M Wenham +23 more
TL;DR: Niraparib (MK4827) as mentioned in this paper is an oral potent, selective PARP-1/PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function.
Journal ArticleDOI
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Marieke Aarts,Rachel Sharpe,Isaac Garcia-Murillas,Heidrun Gevensleben,Melissa S. Hurd,Stuart D. Shumway,Carlo Toniatti,Alan Ashworth,Nicholas C. Turner +8 more
TL;DR: It is shown that p53/p21 inactivation combined with high expression of mitotic cyclins and EZH2 predispose to mitotic entry during S-phase with cells reliant on WEE1 to prevent premature cyclin-dependent kinase (CDK)1 activation.
Journal ArticleDOI
Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR
Heidrun Gevensleben,Isaac Garcia-Murillas,Monika Karla Graeser,Gaia Schiavon,Peter Osin,Marina Parton,Ian E. Smith,Alan Ashworth,Nicholas C. Turner +8 more
TL;DR: Analysis of plasma DNA with digital PCR has the potential to screen for the acquisition of HER2 amplification in metastatic breast cancer and could potentially be adapted to the analysis of any locus amplified in cancer.
Journal ArticleDOI
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Nicholas C. Turner,Nicholas C. Turner,B Kingston,Lucy Kilburn,Sarah Kernaghan,Andrew M Wardley,Andrew M Wardley,Iain R. Macpherson,Richard D. Baird,Rebecca Roylance,Rebecca Roylance,Peter Stephens,Olga Oikonomidou,Jeremy P Braybrooke,Mark Tuthill,Jacinta Abraham,Matthew C Winter,Hannah Bye,Mike Hubank,Mike Hubank,Heidrun Gevensleben,Ros Cutts,Claire Snowdon,Daniel Rea,David Cameron,Abeer M Shaaban,Katrina Randle,Sue Martin,Katie Wilkinson,Laura Moretti,Judith M Bliss,A Ring +31 more
TL;DR: The results demonstrate clinically relevant activity of targeted therapies against rare HER2 and AKT1 mutations, and agreement between ctDNA digital PCR and targeted sequencing was 96–99% (n=800, kappa 0·89–0·93).